References
- Bassand JP, Hamm CW, Ardissino D, Boersma E et al.; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28(13), 1598–1660 (2007).
- Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 29(23), 2909–2945 (2008).
- Mehta SR, Cannon CP, Fox KA et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293(23), 2908–2917 (2005).
- Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33(20), 2569–2619 (2012).
- Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur. Heart J. 31(20), 2501–2555 (2010).
- Davies MJ. The pathophysiology of acute coronary syndromes. Heart 83(3), 361–366 (2000).
- Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295(13), 1531–1538 (2006).
- Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292(13), 1555–1562 (2004).
- Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8), 774–782 (2006).
- Mehran R, Pocock S, Nikolsky E et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc. Interv. 4(6), 654–664 (2011).
- Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7), 853–863 (2003).
- Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 355(21), 2203–2216 (2006).
- Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358(21), 2218–2230 (2008).
- Kastrati A, Neumann FJ, Schulz S et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N. Engl. J. Med. 365(21), 1980–1989 (2011).
- Sibbing D, Busch G, Braun S et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur. Heart J. 29(12), 1504–1509 (2008).
- Summary of product characteristics: Angiox (bivalirudin). The electronic Medicines Compendium (eMC), UK, 2013.
- D'Ascenzo F, Bollati M, Clementi F et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int. J. Cardiol. 167(2), 575–584 (2013).
- Mehran R, Lansky AJ, Witzenbichler B et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374(9696), 1149–1159 (2009).
- Stone GW, Witzenbichler B, Guagliumi G et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377(9784), 2193–2204 (2011).
- Verheugt FW, Steinhubl SR, Hamon M et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc. Interv. 4(2), 191–197 (2011).
- Cohen DJ, Lincoff AM, Lavelle TA et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J. Am. Coll. Cardiol. 44(9), 1792–1800 (2004).
- Pinto DS, Stone GW, Shi C et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J. Am. Coll. Cardiol. 52(22), 1758–1768 (2008).
- Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart 98(7), 544–551 (2012).
- O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127(4), e362–425 (2013).
- Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 57(19), e215–367 (2011).
- Jolly SS, Yusuf S, Cairns J et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 377(9775), 1409–1420 (2011).
- Genereux P, Mehran R, Palmerini T et al. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention 7(8), 905–916 (2011).
- Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
- Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
- Angeras O. Heparin versus bivalirudin in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention. Presented at: EuroPCR 2013. Paris, France, 21–24 May 2013.
Websites
- National Institute for Health and Clinical Excellence. Bivalirudin for the treatment of ST-elevation myocardial infarction. NICE technology appraisal guidance 230 (2011). www.nice.org.uk/guidance/TA230 ( Accessed 9 August 2012)
- National Institute for Health and Clinical Excellence. The early management of unstable angina and non ST segment elevation myocardial infarction. Clinical guideline 94 (2010). www.nice.org.uk/guidance/CG94/Guidance ( Accessed 4 January 2012)
- Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction (BRAVE-4) (2009). http://clinicaltrials.gov/ct2/show/NCT00976092 ( Accessed 3 January 2012)
- Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI (2010). http://clinicaltrials.gov/ct2/show/NCT01158846 ( Accessed 7 July 2010)
- European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (EUROMAX) (2012). http://clinicaltrials.gov/show/NCT01087723 ( Accessed 6 December 2012)
- Bivalirudin versus Heparin in NST and ST-Evaluation myocardial infarction on modern antiplatelet therapy in SCAAR (the VALIDATE - SCAAR-trial). EU Clinical Trials Register (2012). www.clinicaltrialsregister.eu/ctr-search/trial/2012-005260-10/SE ( Accessed 8 January 2013)
- How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention (HEAT-PPCI) (2012). http://clinicaltrials.gov/ct2/show/NCT01519518 ( Accessed 28 September 2012)